Clinical Trial Search

Primary: Provocative Concentration of Methacholine Which Produces a 20% Fall in FEV1 (PC20) — 17.70; 9.88; 20.10; 10.78 mg/mL — p=<0.001

Primary: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan — 100; 100 percentage…

Primary: Number of Participants Who Received Obinutuzumab and Chlorambucil in the Study — 19; 19 participants

Primary: Overall Survival (OS) — 7.3 months

Primary: Objective Response Rate (ORR) — 0 percentage of participants

Primary: SIGH-ADS Depression Score — 10.3; 17.3 units on a scale — p==0.005

Primary: Percentage of Participants by ESA Types at Baseline — 51.5; 17.3; 10.7; 20.4 percentage of participants

Primary: Pneumothorax (Positive or Negative) — 17; 21 participants

Primary: Fever Reduction — -1.5; -0.9 degree Celsius*Time

Primary: 5 Year Distant Disease Free Survival (DDFS) Assessed as Rate of Patients Without Distant Metastases in Subgroup Luminal A vs. Combined Subgroup (Luminal B, HER2…

Primary: Gastrointestinal Side Effects and Quality of Life (Total Score of GSRS) — 46.000; 29.0400; 26.2800; 25.3600 units on a scale

Primary: Depressive Symptoms (Measured With an Abbreviated 10-item CES-D) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months…

Primary: Percentage of Participants Maintaining Hb Concentration Within +/-1 Gram Per Deciliter (g/dL) of Their Reference Hb and Between 10.5 to 12.5 g/dL Throughout the Efficacy…

Primary: American College of Rheumatology 20% (ACR20) Response Rate at Week 12 — 45.1; 58.0; 60.0; 54.0 percentage of participants

Primary: Medically Attended Skin and Soft Tissue Infections (MA-SSI) — 20.9; 17 percentage of partipants